We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Gyros and SCRUM Sign Distribution Agreement for the Japanese Market

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Gyros® AB, a provider of automated micro-immunoassays for the development of biotherapeutics, announces the signing of an exclusive distribution agreement with SCRUM, a major supplier to the Japanese life-science market.

Under the terms of the agreement, SCRUM will market, sell and fully support the Gyros product range, within the Japanese biopharmaceutical, contract research and contract manufacturing industries.

The Gyrolab® system from Gyros is increasingly being employed by biopharmaceutical companies, and their contracted service organizations, during drug development and clinical trials. The company’s success in Europe and the USA has encouraged its expansion into Asia-Pacific, where Japan is regarded as a major market, the company explains.

"We are very happy to have such an experienced and well-established organization as SCRUM representing our products in the Japanese market", commented Erik Wallden, CEO and President of Gyros.

"We believe that Japan represents a key market for us and that this agreement with SCRUM will lead to a significant expansion of our presence in the Asia-Pacific region.”